ASX MEDIA RELEASE 4C Quarterly Activities Report to 30 June 2020 • Annual cash receipts $4.6M – Up 36% • H2 cash receipts of $3.0M delivers profitable & cash flow positive half • Record results despite global restructure and pandemic • New ventilator product set for global release SYDNEY, Australia, Monday 13th July 2020: Uscom Limited (ASX code: UCM) (the Company or Uscom) today released its Appendix 4C – Quarterly Cash flow report for the quarter ending 30 June 2020 (the Quarter). The results disclosed in the attached Appendix 4C are in Australian dollars and prior corresponding period is pcp. ANNUAL SUMMARY UCM CASH RECEIPTS $5.00 Cash receipts $4.60M up 36% (from $3.39M pcp) Net cash flow increases $0.78M (FY20) from decrease $1.29M (FY19) Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: [email protected] W: www

ASX MEDIA RELEASE H2 SUMMARY UCM H2 3.50 Cash Flow Customer Receipts Cash receipts up 84% ($3.02M from $1.64M) Total revenue up 45% ($3.14M from $2.16M) Cash flow positive $0.50M (up $1.45M from cash loss $0.97M in the pcp) Profitable $0.14K (up $0.78M from loss $0.64M pcp) Uscom Limited (ABN 35 091 028 090) Suite 2, Level 8, 66 Clarence Street, Sydney, NSW, 2000, Australia T: +612 9247 4144 E: [email protected] W: www.uscom.c

ASX MEDIA RELEASE Q4 SUMMARY UCM Q4 1.92 Cash Receipts Cash Receipts - $1.00M up 29% (from $0.79M pcp) Sale of Goods – $0.87M up 7% (from $0.81M pcp) Cash Consumption - $0.35M decreased 21% (from $0.45M pcp) Cash on Hand - $1.92M Uscom reports continuing record growth in sales, receipts, profit and cash flow for the year, half and quarter. These results were achieved despite H1 hindered by a global restructure and re-organisation of operations, and H2 impaired by difficult global trading conditions. The Company achieved the Q4 results despite ~$287K foreign exchange losses and ~$123K capital...

ASX MEDIA RELEASE We anticipate USCOM 1A sales to continue to increase as health investment worldwide is focused on refurbishing and building new high-grade critical care centres for treatment of infectious diseases. Growth will be further supplemented by new sales of BP+ and SpiroSonic products as they come to market. Additionally, the Uscom VENTITEST ventilator calibration solution, which is nearing completion, is experiencing strong pre-release dealer interest. Each ventilator worldwide requires calibration to maintain effectiveness and this novel application of Uscom IP establishes new standards...

ASX MEDIA RELEASE About Uscom Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A advanced haemodynamic monitor, Uscom BP+ central blood pressure monitor, and the Uscom SpiroSonic digital ultrasonic spirometers....

Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Name of entity Quarter ended (“current quarter”) Consolidated statement of cash flows Receipts from customers Year to date (12 months) $A’000 Cash flows from operating activities (b) product manufacturing and operating costs administration and corporate costs Dividends received (see note 3) Interest received Interest and other costs of finance paid Income taxes paid Government grants and tax incentives Other (provide details if material) Net cash from / (used in) operating activities Cash flows from investing activities...

Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Consolidated statement of cash flows Year to date (12 months) $A’000 Proceeds from disposal of: (a) entities (b) businesses (c) property, plant and equipment (d) investments (e) intellectual property (f) other non-current assets Cash flows from loans to other entities Dividends received (see note 3) Other (provide details if material) Net cash from / (used in) investing activities Cash flows from financing activities Proceeds from issues of equity securities (excluding convertible debt securities) Transaction costs...

Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Consolidated statement of cash flows Net cash from / (used in) financing activities (item 3.10 above) Year to date (12 months) $A’000 Effect of movement in exchange rates on cash held Cash and cash equivalents at end of period Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts 5.1 Bank balances Call deposits Bank overdrafts Other (provide details) – Term Deposit Cash and cash equivalents at end of quarter...

Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B Financing facilities Note: the term “facility’ includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity. Total facility amount at quarter end $A’000 Amount drawn at quarter end $A’000 Loan facilities Credit standby arrangements Other (please specify) Total financing facilities Unused financing facilities available at quarter end Include in the box below a description of each facility above, including the lender,...

Appendix 4C Quarterly cash flow report for entities subject to Listing Rule 4.7B This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A. This statement gives a true and fair view of the matters disclosed. Authorised by: The Board (Name of body or officer authorising release – see note 4) This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity’s activities for the past quarter, how they have been financed and the effect this has had on its cash position. An...